Mark Fishman

From Wikipedia, the free encyclopedia
Mark Fishman
Residence United States
Fields Medicine, Cardiology
Institutions Novartis Institutes of BioMedical Research, Massachusetts General Hospital, Harvard Medical School
Alma mater Yale College, Harvard Medical School
Known for pioneering Zebrafish research in cardiology
Notable awards Institute of Medicine member, Fellow of the American Academy of Arts and Sciences

Mark Fishman is a noted researcher and clinician in cardiology and the current President of the Novartis Institutes for BioMedical Research (NIBR),[1] the main research arm of Novartis Pharmaceuticals with over 6,700 employees and a 2012 budget of more than $9B.[2]

Fishman was appointed President of the newly founded Novartis Institutes for BioMedical Research in 2002 to implement a new strategy in Novartis' global drug discovery effort.[3] He is the author of over 100 publications[4] and known for pioneering research using the zebrafish as a means of visualizing the development of the circulatory system and as a model for human disease.[5][6][7]

Education

Career

He was previously a Professor of Medicine at Harvard Medical School, Chief of Cardiology at Massachusetts General Hospital, and director of the Cardiovascular Research Center at Massachusetts General Hospital. He is a fellow of the National Academy of Arts and Sciences and a member of the National Academy of Sciences, Institute of Medicine.[8]

References

External links

This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.